Oncology News | pharmaphorum

News

MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.

News

MSD and Daiichi Sankyo's regulatory efforts for their ADCs for cancer have stuttered again, with a withdrawn filing for lung cancer candidate I-DXd.

News

AstraZeneca is closing on FDA approval of a new bladder cancer indication for Imfinzi that could help to fend off encroachment from MSD's Keytruda.

News

FDA expert advisors voted in favour of Grail's Galleri blood test for detecting multiple cancers, but some expressed misgivings about its efficacy.

News

Telix Pharma has reached a deal to acquire ITM, extending a wave of consolidation in the radiopharma category over the last couple of years.

News

AstraZeneca's generalised myasthenia gravis (gMG) therapy Klygefa gets CHMP recommendation, alongside several other novel medicines.